In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Growth

Set Alert for Growth

Fortress Biotech: A Drug Financing Experiment Expands

Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.

Business Strategies Financing Deals
Advertisement

Latest From Growth

Medtech Value Brands: Stepping Down May Boost The Top Line

The medtech industry has traditionally grown through innovation – new products with improved features and benefits have fueled revenue growth. However, innovation alone does not garner the price premium it once did, and manufacturers must decide whether to pursue a value brand strategy alongside their traditional premium brand, says global management consulting firm Simon-Kucher & Partners.

Pricing Strategies Business Strategies

Olympus Dives Back Into M&A With Image Stream Medical Buy

When Olympus Corp. re-entered the M&A arena after five years of "back to the basics," it was via the purchase of a company that meets every parameter of its requirements. Nacho Abia says that OR integrator Image Stream Medical should also help the Japanese multinational stay on course to meet value-based – and ambitious mid-term sales – targets.

Deals M & A

Finding The Right Path To Category Leadership In Oncology

Oncology drug development is undergoing rapid shifts. Bain research shows companies that seek to lead in specific vertical categories outperform rivals that invest across a broad spectrum of cancer targets.

Business Strategies Growth

Regression To The Meanest: How Markets Value Pharma Stocks

Financial markets – the people and institutions that lend companies money and estimate their worth – see pharma companies as revenue-generating, profit-sharing black boxes. Growth earns companies a break from this simplistic view, but sooner or later market valuations of pharmas seem to regress to a mean based on revenue multiples. That mean is getting meaner.

Business Strategies Financing

Managing Pharma's Competing Challenges In The New Health Economy

The shifts roiling the health care industry are creating an entirely new commercial landscape. PwC says that the way pharma companies opt to address three pivotal challenges – patient engagement, analytics and value – will affect not only their future, but the future direction of patient care, provider decisions and payment mechanisms.

Business Strategies Pricing Strategies

Cardio-Neuro Innovator LivaNova Prepares For Challenges Ahead

LivaNova was formed from the merger of cardiovascular disease therapy company Sorin Group and neuromodulation innovator Cyberonics. The role and place in the industry of this new mega group might not be obvious to all, but incoming CEO Damien McDonald already has a vision of creating a disciplined company that leverages synergies and gets closer to the customer base.

Business Strategies Growth
See All
UsernamePublicRestriction

Register